Decreased tear levels of neuromediators are linked to impaired lacrimal function

Article

Decreased tear levels of neuropeptide Y (NPY) and calcitonin gene?related peptide (CGRP) are linked to damaged tear function.

Decreased tear levels of neuropeptide Y (NPY) and calcitonin gene–related peptide (CGRP) are linked to damaged tear function, according to a paper published in the Archives of Ophthalmology.

Dr Alessandro Lambiase et al., Department of Ophthalmology, Campus Bio-Medico, University of Rome, Italy, studied 19 patients with dry eye disease and 12 healthy participants. All patients were examined by slitlamp examination, Schirmer testing, fluorescein staining, and tear film break-up time. Tear samples were gathered, along with the grading of dry eye severity. Substance P, calcitonin gene–related peptide (CGRP), neuropeptide Y (NPY), vasoactive intestinal peptide, and nerve growth factor (NGF) concentrations were assessed by enzyme-linked immunoassay and linked to the clinical results.

It was found that nerve growth factor tear levels were significantly higher in patients with dry eye disease. CGRP and NPY concentrations were significantly reduced compared to healthy participants.

The severity of dry eye was directly linked to NGF and inversely correlated with CGRP and NPY tear levels. Conjunctival hyperemia and fluorescein staining results were directly correlated with nerve growth tear factor.

CGRP was directly linked to Schirmer test results and NPY was inversely linked to tear film break-up time. NGF tear levels strongly correlate with corneal epithelial damage. The study suggests the importance of NPY, CRGP and NGF as markers of dry eye severity.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.